+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Age Related Macular Degeneration Drug Market - Global Forecast 2026-2032- Product Image
Age Related Macular Degeneration Drug Market - Global Forecast 2026-2032- Product Image
Sale

Age Related Macular Degeneration Drug Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6277719
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Age-Related Macular Degeneration Drugs: Executive Overview

Age-related macular degeneration (AMD) is a leading cause of irreversible central vision loss, particularly among older adults. Drug development and clinical practice focus mainly on slowing disease progression, preserving visual function, and improving treatment convenience. The therapeutic landscape includes intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapies for neovascular AMD and complement-pathway medicines for geographic atrophy, alongside continuing research into longer-acting delivery systems, novel biological targets, and earlier intervention.

Treatment Is Shifting Toward Durability and Earlier Disease Management

The AMD drug landscape is being reshaped by the need to reduce injection frequency, improve adherence, and address disease before substantial retinal damage occurs. Longer-acting formulations, implantable delivery approaches, home-monitoring tools, and treatment protocols guided by retinal imaging are influencing care pathways. At the same time, geographic atrophy has expanded the clinical focus beyond neovascular disease, creating greater interest in complement inhibition and biomarker-led patient selection. These changes increase the importance of coordinated ophthalmology services, reimbursement support, and patient education.

Artificial Intelligence Strengthens Detection, Monitoring, and Trial Design

Artificial intelligence is increasingly applied to retinal image interpretation, risk stratification, disease monitoring, and clinical-trial workflows. Machine-learning systems can help identify fluid, atrophy, and progression patterns in optical coherence tomography and fundus images, supporting earlier referral and more consistent follow-up. AI may also improve trial recruitment and endpoint assessment, but clinical validation, interoperability, cybersecurity, explainability, and regulatory oversight remain essential. Its greatest near-term value is likely to come from augmenting ophthalmologists rather than replacing clinical judgment.

Regional Insights: Access and Delivery Models Differ Across Six Major Regions

North America benefits from advanced retinal services, broad clinical-trial activity, and established reimbursement pathways, while affordability and treatment burden remain important access constraints. Europe combines sophisticated specialist care with country-level differences in approval, reimbursement, and capacity. Asia-Pacific includes highly developed systems such as Japan, Australia, and South Korea alongside rapidly expanding but uneven access in other markets. Latin America faces disparities in specialist availability, diagnosis, and medicine affordability. The Middle East is investing in tertiary healthcare and digital diagnostics, although access varies substantially between countries. Africa continues to face shortages of ophthalmologists, diagnostic equipment, and consistent treatment infrastructure, making screening partnerships and decentralized care especially relevant.

Group Insights: Economic and Policy Blocs Shape Adoption Conditions

ASEAN markets are characterized by varied healthcare financing, urban concentration of specialist services, and growing interest in teleophthalmology and regional capacity building. BRICS countries combine substantial clinical need with differing regulatory systems, public procurement structures, and domestic manufacturing capabilities. The European Union benefits from regulatory coordination, but reimbursement and service delivery remain nationally determined. G7 members generally have strong research ecosystems and specialist infrastructure while confronting aging populations, workforce pressures, and budget scrutiny. GCC countries are strengthening tertiary ophthalmic care and digital health capabilities, with access shaped by public-sector investment and expatriate populations. NATO members span diverse health systems, yet many can benefit from shared preparedness, research, and standards for digitally enabled eye care.

Country Insights: Diverse Priorities Across Fifteen National Markets

Australia emphasizes specialist retinal care, universal coverage, and rural access. Brazil and Mexico must address geographic disparities, affordability, and public-system capacity. Canada faces long travel distances in some communities and pressure on specialist availability. China is expanding ophthalmic infrastructure and domestic innovation while managing regional differences in access. France, Germany, Italy, Spain, and the United Kingdom combine strong clinical expertise with reimbursement, waiting-time, and workforce considerations that differ by national system. India has major unmet need alongside rapidly developing private, public, and teleophthalmology networks. Japan has an aging population and sophisticated retinal services, with adherence and treatment burden remaining important. South Korea combines advanced digital and clinical capabilities with an aging demographic. Russia’s access is influenced by regional infrastructure, procurement, and broader healthcare constraints. The United States has extensive specialist and research capacity, but insurance coverage, out-of-pocket costs, and injection logistics remain central considerations.

Action Priorities for Leaders: Improve Durability, Equity, and Evidence Quality

Industry leaders should prioritize therapies and delivery systems that reduce treatment burden without compromising retinal outcomes. They should generate real-world evidence on adherence, functional vision, safety, and outcomes across underserved populations, while designing access programs that address transportation, affordability, and caregiver support. Partnerships with health systems can expand imaging capacity and nurse-led coordination, and validated AI tools can help triage referrals and monitor disease when integrated with clinician oversight. Clear evidence packages aligned with country-specific reimbursement requirements, transparent safety communication, and responsible data governance will be important for sustainable adoption.

Research Methodology: Evidence-Led Synthesis of AMD Drug Landscape

This executive summary uses a structured synthesis of established clinical, regulatory, epidemiological, and health-system evidence relevant to AMD drug development and use. The assessment distinguishes neovascular AMD from geographic atrophy and considers treatment mechanisms, delivery approaches, diagnostic technologies, access conditions, and implementation barriers. Regional, group, and country observations are framed qualitatively and avoid unsupported numerical claims. Interpretation should be updated as peer-reviewed findings, regulatory decisions, clinical guidelines, reimbursement policies, and post-market safety evidence evolve.

Conclusion: Progress Depends on Better Outcomes and Broader Access

AMD drug innovation is moving from a narrow focus on controlling neovascular activity toward a broader objective: preserving vision across disease stages while making care more durable and accessible. Complement-pathway research, extended delivery, imaging, and AI are expanding the available toolkit, but their impact will depend on evidence quality, specialist capacity, affordability, and reliable follow-up. Leaders that combine clinical effectiveness with practical delivery models and equitable access will be best positioned to improve outcomes for aging populations worldwide.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Age Related Macular Degeneration Drug Market, by Drug
7.1. Introduction
7.2. Aflibercept
7.3. Bevacizumab
7.4. Brolucizumab
7.5. Emerging Clinical Candidates
7.6. Faricimab
7.7. Gene Therapy Candidates
7.7.1. Approved Gene Therapies
7.7.2. Clinical Stage Gene Candidates
7.8. Pegcetacoplan And Other Complement Inhibitors
7.9. Ranibizumab
8. Age Related Macular Degeneration Drug Market, by Therapy Class
8.1. Introduction
8.2. Anti-Vegf Therapies
8.3. Complement Inhibitors
8.4. Corticosteroids
8.5. Gene Therapy
8.6. Small Molecule Inhibitors
9. Age Related Macular Degeneration Drug Market, by Patient Type
9.1. Introduction
9.2. Early And Intermediate AMD
9.3. Geographic Atrophy Dry AMD
9.4. Neovascular Wet AMD
10. Age Related Macular Degeneration Drug Market, by Formulation
10.1. Introduction
10.2. Intravitreal Implant And Sustained Release
10.3. Intravitreal Injection
10.4. Ocular Inserts And Other
10.5. Oral Formulations
10.6. Topical Drops
11. Age Related Macular Degeneration Drug Market, by Route Of Administration
11.1. Introduction
11.2. Intravitreal
11.3. Subretinal
11.4. Systemic
11.5. Topical
12. Age Related Macular Degeneration Drug Market, by Dosing Regimen
12.1. Introduction
12.2. Fixed Bimonthly And Extended Interval
12.3. Monthly
12.4. Prn As Needed
12.5. Single Dose Gene Therapy
12.6. Treat-And-Extend
13. Age Related Macular Degeneration Drug Market, by Care Setting
13.1. Introduction
13.2. Ambulatory Surgical Centers
13.3. Home Healthcare Administration
13.4. Hospital Outpatient Departments
13.5. Outpatient Ophthalmology And Retina Clinics
13.6. Specialty Eye Hospitals
14. Age Related Macular Degeneration Drug Market, by Payer Type
14.1. Introduction
14.2. Commercial Insurance
14.3. Medicaid
14.4. Medicare
14.5. Out Of Pocket
15. Age Related Macular Degeneration Drug Market, by Manufacturer Type
15.1. Introduction
15.2. Compounding Pharmacies
15.3. Integrated Big Pharma
15.4. Large Biotech
15.5. Specialty Pharma And Contract Manufacturers
16. Age Related Macular Degeneration Drug Market, by Regulatory Status
16.1. Introduction
16.2. Approved Marketed
16.3. Clinical Trials And Emerging
16.4. Off Label Use
16.5. Withdrawn Discontinued
17. Age Related Macular Degeneration Drug Market, by Distribution Channel
17.1. Introduction
17.2. Online
17.3. Offline
18. Age Related Macular Degeneration Drug Market, by Region
18.1. Introduction
18.2. Asia-Pacific
18.3. North America
18.4. Latin America
18.5. Europe
18.6. Middle East
18.7. Africa
19. Age Related Macular Degeneration Drug Market, by Group
19.1. Introduction
19.2. ASEAN
19.3. GCC
19.4. European Union
19.5. BRICS
19.6. G7
19.7. NATO
20. Age Related Macular Degeneration Drug Market, by Country
20.1. Introduction
20.2. United States
20.3. Canada
20.4. Mexico
20.5. Brazil
20.6. United Kingdom
20.7. Germany
20.8. France
20.9. Russia
20.10. Italy
20.11. Spain
20.12. China
20.13. India
20.14. Japan
20.15. Australia
20.16. South Korea
21. Competitive Landscape
21.1. Market Share Analysis, 2025
21.2. Market Concentration Analysis, 2025
21.2.1. Concentration Ratio (CR)
21.2.2. Herfindahl Hirschman Index (HHI)
21.3. Recent Developments & Impact Analysis, 2025
21.4. Product Portfolio Analysis, 2025
21.5. Benchmarking Analysis, 2025
22. Company Profiles
22.1. 4D Molecular Therapeutics Inc.
22.2. AbbVie Inc.
22.3. Alcon Inc.
22.4. Alkeus Pharmaceuticals Inc.
22.5. Apellis Pharmaceuticals Inc.
22.6. Astellas Pharma Inc.
22.7. Aviceda Therapeutics Inc.
22.8. Bausch Health Companies Inc.
22.9. Bayer AG
22.10. Belite Bio Inc.
22.11. Biogen Inc.
22.12. Chengdu Kanghong Pharmaceutical Group Co. Ltd.
22.13. F. Hoffmann-La Roche Ltd
22.14. Genentech Inc.
22.15. Intas Pharmaceuticals Ltd.
22.16. Kodiak Sciences Inc.
22.17. Lineage Cell Therapeutics Inc.
22.18. Novartis AG
22.19. Ocular Therapeutix Inc.
22.20. Opthea Limited
22.21. Outlook Therapeutics Inc.
22.22. Regeneron Pharmaceuticals Inc.
22.23. REGENXBIO Inc.
22.24. Santen Pharmaceutical Co. Ltd.
22.25. Stealth BioTherapeutics Inc.
23. Key Experts
LIST OF FIGURES
FIGURE 1. Global Age Related Macular Degeneration Drug Market, Years Considered for the Study
FIGURE 2. Global Age Related Macular Degeneration Drug Market, Research Design
FIGURE 3. Global Age Related Macular Degeneration Drug Market, Research Framework
FIGURE 4. Global Age Related Macular Degeneration Drug Market, Data Triangulation
FIGURE 5. Global Age Related Macular Degeneration Drug Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Age Related Macular Degeneration Drug Market Size, by Drug, 2025 vs 2032 (%)
FIGURE 7. Global Age Related Macular Degeneration Drug Market Size, by Drug, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Age Related Macular Degeneration Drug Market Size, by Therapy Class, 2025 vs 2032 (%)
FIGURE 9. Global Age Related Macular Degeneration Drug Market Size, by Therapy Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Age Related Macular Degeneration Drug Market Size, by Patient Type, 2025 vs 2032 (%)
FIGURE 11. Global Age Related Macular Degeneration Drug Market Size, by Patient Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Age Related Macular Degeneration Drug Market Size, by Formulation, 2025 vs 2032 (%)
FIGURE 13. Global Age Related Macular Degeneration Drug Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Age Related Macular Degeneration Drug Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 15. Global Age Related Macular Degeneration Drug Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Age Related Macular Degeneration Drug Market Size, by Dosing Regimen, 2025 vs 2032 (%)
FIGURE 17. Global Age Related Macular Degeneration Drug Market Size, by Dosing Regimen, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Age Related Macular Degeneration Drug Market Size, by Care Setting, 2025 vs 2032 (%)
FIGURE 19. Global Age Related Macular Degeneration Drug Market Size, by Care Setting, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Age Related Macular Degeneration Drug Market Size, by Payer Type, 2025 vs 2032 (%)
FIGURE 21. Global Age Related Macular Degeneration Drug Market Size, by Payer Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global Age Related Macular Degeneration Drug Market Size, by Manufacturer Type, 2025 vs 2032 (%)
FIGURE 23. Global Age Related Macular Degeneration Drug Market Size, by Manufacturer Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 24. Global Age Related Macular Degeneration Drug Market Size, by Regulatory Status, 2025 vs 2032 (%)
FIGURE 25. Global Age Related Macular Degeneration Drug Market Size, by Regulatory Status, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 26. Global Age Related Macular Degeneration Drug Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 27. Global Age Related Macular Degeneration Drug Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 28. Global Age Related Macular Degeneration Drug Market Size, by Region, 2025 vs 2032 (%)
FIGURE 29. Global Age Related Macular Degeneration Drug Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 30. Global Age Related Macular Degeneration Drug Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 31. Global Age Related Macular Degeneration Drug Market Size, by Country, 2025 vs 2032 (%)
FIGURE 32. Global Age Related Macular Degeneration Drug Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 33. Global Age Related Macular Degeneration Drug Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Age Related Macular Degeneration Drug Market Segmentation & Coverage
TABLE 2. Global Age Related Macular Degeneration Drug Market Size, 2017-2032 (USD Million)
TABLE 3. Global Age Related Macular Degeneration Drug Market Size, by Drug, 2017-2032 (USD Million)
TABLE 4. Global Aflibercept Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Aflibercept Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Aflibercept Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Bevacizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Bevacizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Bevacizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Brolucizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Brolucizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Brolucizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Emerging Clinical Candidates Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Emerging Clinical Candidates Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Emerging Clinical Candidates Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Faricimab Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Faricimab Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Faricimab Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Gene Therapy Candidates Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Gene Therapy Candidates Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Gene Therapy Candidates Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Approved Gene Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Approved Gene Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Approved Gene Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Clinical Stage Gene Candidates Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Clinical Stage Gene Candidates Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Clinical Stage Gene Candidates Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Pegcetacoplan And Other Complement Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Pegcetacoplan And Other Complement Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Pegcetacoplan And Other Complement Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Ranibizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Ranibizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Ranibizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Age Related Macular Degeneration Drug Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 35. Global Anti-Vegf Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Anti-Vegf Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Anti-Vegf Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Complement Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Complement Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Complement Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Corticosteroids Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Corticosteroids Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Corticosteroids Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Small Molecule Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Small Molecule Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Small Molecule Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Age Related Macular Degeneration Drug Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 51. Global Early And Intermediate AMD Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Early And Intermediate AMD Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Early And Intermediate AMD Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Geographic Atrophy Dry AMD Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Geographic Atrophy Dry AMD Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Geographic Atrophy Dry AMD Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Neovascular Wet AMD Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Neovascular Wet AMD Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Neovascular Wet AMD Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Age Related Macular Degeneration Drug Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 61. Global Intravitreal Implant And Sustained Release Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Intravitreal Implant And Sustained Release Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Intravitreal Implant And Sustained Release Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Intravitreal Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Intravitreal Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Intravitreal Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Ocular Inserts And Other Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Ocular Inserts And Other Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Ocular Inserts And Other Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Oral Formulations Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Oral Formulations Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Oral Formulations Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Topical Drops Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Topical Drops Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Topical Drops Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Age Related Macular Degeneration Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 77. Global Intravitreal Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Intravitreal Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Intravitreal Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Subretinal Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Subretinal Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Subretinal Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Systemic Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Systemic Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Systemic Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Topical Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Topical Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Topical Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Age Related Macular Degeneration Drug Market Size, by Dosing Regimen, 2017-2032 (USD Million)
TABLE 90. Global Fixed Bimonthly And Extended Interval Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Fixed Bimonthly And Extended Interval Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Fixed Bimonthly And Extended Interval Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Monthly Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Monthly Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Monthly Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Prn As Needed Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Prn As Needed Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Prn As Needed Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Single Dose Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global Single Dose Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global Single Dose Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Treat-And-Extend Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Global Treat-And-Extend Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. Global Treat-And-Extend Market Size, by Country, 2017-2032 (USD Million)
TABLE 105. Global Age Related Macular Degeneration Drug Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 106. Global Ambulatory Surgical Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Ambulatory Surgical Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Ambulatory Surgical Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Home Healthcare Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Home Healthcare Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Home Healthcare Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Hospital Outpatient Departments Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Global Hospital Outpatient Departments Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. Global Hospital Outpatient Departments Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. Global Outpatient Ophthalmology And Retina Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Global Outpatient Ophthalmology And Retina Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. Global Outpatient Ophthalmology And Retina Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. Global Specialty Eye Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Global Specialty Eye Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. Global Specialty Eye Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 121. Global Age Related Macular Degeneration Drug Market Size, by Payer Type, 2017-2032 (USD Million)
TABLE 122. Global Commercial Insurance Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Global Commercial Insurance Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. Global Commercial Insurance Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. Global Medicaid Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global Medicaid Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global Medicaid Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global Medicare Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Global Medicare Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. Global Medicare Market Size, by Country, 2017-2032 (USD Million)
TABLE 131. Global Out Of Pocket Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Global Out Of Pocket Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. Global Out Of Pocket Market Size, by Country, 2017-2032 (USD Million)
TABLE 134. Global Age Related Macular Degeneration Drug Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 135. Global Compounding Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 136. Global Compounding Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. Global Compounding Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 138. Global Integrated Big Pharma Market Size, by Region, 2017-2032 (USD Million)
TABLE 139. Global Integrated Big Pharma Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. Global Integrated Big Pharma Market Size, by Country, 2017-2032 (USD Million)
TABLE 141. Global Large Biotech Market Size, by Region, 2017-2032 (USD Million)
TABLE 142. Global Large Biotech Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. Global Large Biotech Market Size, by Country, 2017-2032 (USD Million)
TABLE 144. Global Specialty Pharma And Contract Manufacturers Market Size, by Region, 2017-2032 (USD Million)
TABLE 145. Global Specialty Pharma And Contract Manufacturers Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. Global Specialty Pharma And Contract Manufacturers Market Size, by Country, 2017-2032 (USD Million)
TABLE 147. Global Age Related Macular Degeneration Drug Market Size, by Regulatory Status, 2017-2032 (USD Million)
TABLE 148. Global Approved Marketed Market Size, by Region, 2017-2032 (USD Million)
TABLE 149. Global Approved Marketed Market Size, by Group, 2017-2032 (USD Million)
TABLE 150. Global Approved Marketed Market Size, by Country, 2017-2032 (USD Million)
TABLE 151. Global Clinical Trials And Emerging Market Size, by Region, 2017-2032 (USD Million)
TABLE 152. Global Clinical Trials And Emerging Market Size, by Group, 2017-2032 (USD Million)
TABLE 153. Global Clinical Trials And Emerging Market Size, by Country, 2017-2032 (USD Million)
TABLE 154. Global Off Label Use Market Size, by Region, 2017-2032 (USD Million)
TABLE 155. Global Off Label Use Market Size, by Group, 2017-2032 (USD Million)
TABLE 156. Global Off Label Use Market Size, by Country, 2017-2032 (USD Million)
TABLE 157. Global Withdrawn Discontinued Market Size, by Region, 2017-2032 (USD Million)
TABLE 158. Global Withdrawn Discontinued Market Size, by Group, 2017-2032 (USD Million)
TABLE 159. Global Withdrawn Discontinued Market Size, by Country, 2017-2032 (USD Million)
TABLE 160. Global Age Related Macular Degeneration Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 161. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 162. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 163. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 164. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 165. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 166. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 167. Global Age Related Macular Degeneration Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 168. Asia-Pacific Age Related Macular Degeneration Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 169. Asia-Pacific Age Related Macular Degeneration Drug Market Size, by Drug, 2017-2032 (USD Million)
TABLE 170. Asia-Pacific Age Related Macular Degeneration Drug Market Size, by Gene Therapy Candidates, 2017-2032 (USD Million)
TABLE 171. Asia-Pacific Age Related Macular Degeneration Drug Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 172. Asia-Pacific Age Related Macular Degeneration Drug Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 173. Asia-Pacific Age Related Macular Degeneration Drug Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 174. Asia-Pacific Age Related Macular Degeneration Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 175. Asia-Pacific Age Related Macular Degeneration Drug Market Size, by Dosing Regimen, 2017-2032 (USD Million)
TABLE 176. Asia-Pacific Age Related Macular Degeneration Drug Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 177. Asia-Pacific Age Related Macular Degeneration Drug Market Size, by Payer Type, 2017-2032 (USD Million)
TABLE 178. Asia-Pacific Age Related Macular Degeneration Drug Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 179. Asia-Pacific Age Related Macular Degeneration Drug Market Size, by Regulatory Status, 2017-2032 (USD Million)
TABLE 180. Asia-Pacific Age Related Macular Degeneration Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 181. North America Age Related Macular Degeneration Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 182. North America Age Related Macular Degeneration Drug Market Size, by Drug, 2017-2032 (USD Million)
TABLE 183. North America Age Related Macular Degeneration Drug Market Size, by Gene Therapy Candidates, 2017-2032 (USD Million)
TABLE 184. North America Age Related Macular Degeneration Drug Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 185. North America Age Related Macular Degeneration Drug Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 186. North America Age Related Macular Degeneration Drug Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 187. North America Age Related Macular Degeneration Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 188. North America Age Related Macular Degeneration Drug Market Size, by Dosing Regimen, 2017-2032 (USD Million)
TABLE 189. North America Age Related Macular Degeneration Drug Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 190. North America Age Related Macular Degeneration Drug Market Size, by Payer Type, 2017-2032 (USD Million)
TABLE 191. North America Age Related Macular Degeneration Drug Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 192. North America Age Related Macular Degeneration Drug Market Size, by Regulatory Status, 2017-2032 (USD Million)
TABLE 193. North America Age Related Macular Degeneration Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 194. Latin America Age Related Macular Degeneration Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 195. Latin America Age Related Macular Degeneration Drug Market Size, by Drug, 2017-2032 (USD Million)
TABLE 196. Latin America Age Related Macular Degeneration Drug Market Size, by Gene Therapy Candidates, 2017-2032 (USD Million)
TABLE 197. Latin America Age Related Macular Degeneration Drug Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 198. Latin America Age Related Macular Degeneration Drug Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 199. Latin America Age Related Macular Degeneration Drug Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 200. Latin America Age Related Macular Degeneration Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 201. Latin America Age Related Macular Degeneration Drug Market Size, by Dosing Regimen, 2017-2032 (USD Million)
TABLE 202. Latin America Age Related Macular Degeneration Drug Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 203. Latin America Age Related Macular Degeneration Drug Market Size, by Payer Type, 2017-2032 (USD Million)
TABLE 204. Latin America Age Related Macular Degeneration Drug Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 205. Latin America Age Related Macular Degeneration Drug Market Size, by Regulatory Status, 2017-2032 (USD Million)
TABLE 206. Latin America Age Related Macular Degeneration Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 207. Europe Age Related Macular Degeneration Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 208. Europe Age Related Macular Degeneration Drug Market Size, by Drug, 2017-2032 (USD Million)
TABLE 209. Europe Age Related Macular Degeneration Drug Market Size, by Gene Therapy Candidates, 2017-2032 (USD Million)
TABLE 210. Europe Age Related Macular Degeneration Drug Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 211. Europe Age Related Macular Degeneration Drug Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 212. Europe Age Related Macular Degeneration Drug Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 213. Europe Age Related Macular Degeneration Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 214. Europe Age Related Macular Degeneration Drug Market Size, by Dosing Regimen, 2017-2032 (USD Million)
TABLE 215. Europe Age Related Macular Degeneration Drug Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 216. Europe Age Related Macular Degeneration Drug Market Size, by Payer Type, 2017-2032 (USD Million)
TABLE 217. Europe Age Related Macular Degeneration Drug Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 218. Europe Age Related Macular Degeneration Drug Market Size, by Regulatory Status, 2017-2032 (USD Million)
TABLE 219. Europe Age Related Macular Degeneration Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 220. Middle East Age Related Macular Degeneration Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 221. Middle East Age Related Macular Degeneration Drug Market Size, by Drug, 2017-2032 (USD Million)
TABLE 222. Middle East Age Related Macular Degeneration Drug Market Size, by Gene Therapy Candidates, 2017-2032 (USD Million)
TABLE 223. Middle East Age Related Macular Degeneration Drug Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 224. Middle East Age Related Macular Degeneration Drug Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 225. Middle East Age Related Macular Degeneration Drug Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 226. Middle East Age Related Macular Degeneration Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 227. Middle East Age Related Macular Degeneration Drug Market Size, by Dosing Regimen, 2017-2032 (USD Million)
TABLE 228. Middle East Age Related Macular Degeneration Drug Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 229. Middle East Age Related Macular Degeneration Drug Market Size, by Payer Type, 2017-2032 (USD Million)
TABLE 230. Middle East Age Related Macular Degeneration Drug Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 231. Middle East Age Related Macular Degeneration Drug Market Size, by Regulatory Status, 2017-2032 (USD Million)
TABLE 232. Middle East Age Related Macular Degeneration Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 233. Africa Age Related Macular Degeneration Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 234. Africa Age Related Macular Degeneration Drug Market Size, by Drug, 2017-2032 (USD Million)
TABLE 235. Africa Age Related Macular Degeneration Drug Market Size, by Gene Therapy Candidates, 2017-2032 (USD Million)
TABLE 236. Africa Age Related Macular Degeneration Drug Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 237. Africa Age Related Macular Degeneration Drug Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 238. Africa Age Related Macular Degeneration Drug Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 239. Africa Age Related Macular Degeneration Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 240. Africa Age Related Macular Degeneration Drug Market Size, by Dosing Regimen, 2017-2032 (USD Million)
TABLE 241. Africa Age Related Macular Degeneration Drug Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 242. Africa Age Related Macular Degeneration Drug Market Size, by Payer Type, 2017-2032 (USD Million)
TABLE 243. Africa Age Related Macular Degeneration Drug Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 244. Africa Age Related Macular Degeneration Drug Market Size, by Regulatory Status, 2017-2032 (USD Million)
TABLE 245. Africa Age Related Macular Degeneration Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 246. Global Age Related Macular Degeneration Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 247. ASEAN Age Related Macular Degeneration Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 248. ASEAN Age Related Macular Degeneration Drug Market Size, by Drug, 2017-2032 (USD Million)
TABLE 249. ASEAN Age Related Macular Degeneration Drug Market Size, by Gene Therapy Candidates, 2017-2032 (USD Million)
TABLE 250. ASEAN Age Related Macular Degeneration Drug Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 251. ASEAN Age Related Macular Degeneration Drug Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 252. ASEAN Age Related Macular Degeneration Drug Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 253. ASEAN Age Related Macular Degeneration Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 254. ASEAN Age Related Macular Degeneration Drug Market Size, by Dosing Regimen, 2017-2032 (USD Million)
TABLE 255. ASEAN Age Related Macular Degeneration Drug Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 256. ASEAN Age Related Macular Degeneration Drug Market Size, by Payer Type, 2017-2032 (USD Million)
TABLE 257. ASEAN Age Related Macular Degeneration Drug Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 258. ASEAN Age Related Macular Degeneration Drug Market Size, by Regulatory Status, 2017-2032 (USD Million)
TABLE 259. ASEAN Age Related Macular Degeneration Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 260. GCC Age Related Macular Degeneration Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 261. GCC Age Related Macular Degeneration Drug Market Size, by Drug, 2017-2032 (USD Million)
TABLE 262. GCC Age Related Macular Degeneration Drug Market Size, by Gene Therapy Candidates, 2017-2032 (USD Million)
TABLE 263. GCC Age Related Macular Degeneration Drug Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 264. GCC Age Related Macular Degeneration Drug Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 265. GCC Age Related Macular Degeneration Drug Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 266. GCC Age Related Macular Degeneration Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 267. GCC Age Related Macular Degeneration Drug Market Size, by Dosing Regimen, 2017-2032 (USD Million)
TABLE 268. GCC Age Related Macular Degeneration Drug Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 269. GCC Age Related Macular Degeneration Drug Market Size, by Payer Type, 2017-2032 (USD Million)
TABLE 270. GCC Age Related Macular Degeneration Drug Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 271. GCC Age Related Macular Degeneration Drug Market Size, by Regulatory Status, 2017-2032 (USD Million)
TABLE 272. GCC Age Related Macular Degeneration Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 273. European Union Age Related Macular Degeneration Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 274. European Union Age Related Macular Degeneration Drug Market Size, by Drug, 2017-2032 (USD Million)
TABLE 275. European Union Age Related Macular Degeneration Drug Market Size, by Gene Therapy Candidates, 2017-2032 (USD Million)
TABLE 276. European Union Age Related Macular Degeneration Drug Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 277. European Union Age Related Macular Degeneration Drug Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 278. European Union Age Related Macular Degeneration Drug Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 279. European Union Age Related Macular Degeneration Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 280. European Union Age Related Macular Degeneration Drug Market Size, by Dosing Regimen, 2017-2032 (USD Million)
TABLE 281. European Union Age Related Macular Degeneration Drug Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 282. European Union Age Related Macular Degeneration Drug Market Size, by Payer Type, 2017-2032 (USD Million)
TABLE 283. European Union Age Related Macular Degeneration Drug Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 284. European Union Age Related Macular Degeneration Drug Market Size, by Regulatory Status, 2017-2032 (USD Million)
TABLE 285. European Union Age Related Macular Degeneration Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 286. BRICS Age Related Macular Degeneration Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 287. BRICS Age Related Macular Degeneration Drug Market Size, by Drug, 2017-2032 (USD Million)
TABLE 288. BRICS Age Related Macular Degeneration Drug Market Size, by Gene Therapy Candidates, 2017-2032 (USD Million)
TABLE 289. BRICS Age Related Macular Degeneration Drug Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 290. BRICS Age Related Macular Degeneration Drug Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 291. BRICS Age Related Macular Degeneration Drug Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 292. BRICS Age Related Macular Degeneration Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 293. BRICS Age Related Macular Degeneration Drug Market Size, by Dosing Regimen, 2017-2032 (USD Million)
TABLE 294. BRICS Age Related Macular Degeneration Drug Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 295. BRICS Age Related Macular Degeneration Drug Market Size, by Payer Type, 2017-2032 (USD Million)
TABLE 296. BRICS Age Related Macular Degeneration Drug Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 297. BRICS Age Related Macular Degeneration Drug Market Size, by Regulatory Status, 2017-2032 (USD Million)
TABLE 298. BRICS Age Related Macular Degeneration Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 299. G7 Age Related Macular Degeneration Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 300. G7 Age Related Macular Degeneration Drug Market Size, by Drug, 2017-2032 (USD Million)
TABLE 301. G7 Age Related Macular Degeneration Drug Market Size, by Gene Therapy Candidates, 2017-2032 (USD Million)
TABLE 302. G7 Age Related Macular Degeneration Drug Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 303. G7 Age Related Macular Degeneration Drug Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 304. G7 Age Related Macular Degeneration Drug Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 305. G7 Age Related Macular Degeneration Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 306. G7 Age Related Macular Degeneration Drug Market Size, by Dosing Regimen, 2017-2032 (USD Million)
TABLE 307. G7 Age Related Macular Degeneration Drug Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 308. G7 Age Related Macular Degeneration Drug Market Size, by Payer Type, 2017-2032 (USD Million)
TABLE 309. G7 Age Related Macular Degeneration Drug Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 310. G7 Age Related Macular Degeneration Drug Market Size, by Regulatory Status, 2017-2032 (USD Million)
TABLE 311. G7 Age Related Macular Degeneration Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 312. NATO Age Related Macular Degeneration Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 313. NATO Age Related Macular Degeneration Drug Market Size, by Drug, 2017-2032 (USD Million)
TABLE 314. NATO Age Related Macular Degeneration Drug Market Size, by Gene Therapy Candidates, 2017-2032 (USD Million)
TABLE 315. NATO Age Related Macular Degeneration Drug Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 316. NATO Age Related Macular Degeneration Drug Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 317. NATO Age Related Macular Degeneration Drug Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 318. NATO Age Related Macular Degeneration Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 319. NATO Age Related Macular Degeneration Drug Market Size, by Dosing Regimen, 2017-2032 (USD Million)
TABLE 320. NATO Age Related Macular Degeneration Drug Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 321. NATO Age Related Macular Degeneration Drug Market Size, by Payer Type, 2017-2032 (USD Million)
TABLE 322. NATO Age Related Macular Degeneration Drug Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 323. NATO Age Related Macular Degeneration Drug Market Size, by Regulatory Status, 2017-2032 (USD Million)
TABLE 324. NATO Age Related Macular Degeneration Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 325. Global Age Related Macular Degeneration Drug Market Size, by Country, 2017-2032 (USD Million)
TABLE 326. United States Age Related Macular Degeneration Drug Market Size, 2017-2032 (USD Million)
TABLE 32

Companies Mentioned

  • 4D Molecular Therapeutics Inc.
  • AbbVie Inc.
  • Alcon Inc.
  • Alkeus Pharmaceuticals Inc.
  • Apellis Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • Aviceda Therapeutics Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Belite Bio Inc.
  • Biogen Inc.
  • Chengdu Kanghong Pharmaceutical Group Co. Ltd.
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc.
  • Intas Pharmaceuticals Ltd.
  • Kodiak Sciences Inc.
  • Lineage Cell Therapeutics Inc.
  • Novartis AG
  • Ocular Therapeutix Inc.
  • Opthea Limited
  • Outlook Therapeutics Inc.
  • Regeneron Pharmaceuticals Inc.
  • REGENXBIO Inc.
  • Santen Pharmaceutical Co. Ltd.
  • Stealth BioTherapeutics Inc.

Related Topics

Related Reports

Neovascular Age-Related Macular Degeneration Treatment Market Report and Forecast 2024-2032 - Product Image

Neovascular Age-Related Macular Degeneration Treatment Market Report and Forecast 2024-2032

  • Report
  • 160 Pages
  • Global
From
Ophthalmic Drugs Market - Global Forecast 2026-2032 - Product Image

Ophthalmic Drugs Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Wet Age-Related Macular Degeneration (Wet AMD) - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Wet Age-Related Macular Degeneration (Wet AMD) - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Macular Degeneration Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Macular Degeneration Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 212 Pages
  • Global
From
Macular Degeneration Treatment Market Report by Type, Stage of Disease, Route of Administration, End User, and Region 2026-2034 - Product Image

Macular Degeneration Treatment Market Report by Type, Stage of Disease, Route of Administration, End User, and Region 2026-2034

  • Report
  • 149 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.